---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-065184"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T01:00:00.678553+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q4 net sales $219.9M, net loss narrows; FY26 guidance $850-860M sales, $95-98M adj. EBITDA

## Summary
- Q4 net loss $(2.2)M vs $(29.1)M YoY; adjusted EBITDA $29.2M (13.4% margin), up 230 bps.
- Full-year 2025 net sales $822.3M (+2.9% reported); pro forma $811.9M (+4.1% constant currency).
- FY25 net loss $(92.2)M, improved from $(126.0)M; free cash flow $3.1M (ex-M6 restructuring).
- 2026 guidance: net sales $850-860M (~5.5% pro forma CC growth); adj. EBITDA $95-98M.
- Three-year targets (2026-28): 6.5-7.5% sales CAGR, mid-teens EBITDA margin by 2028, positive FCF.

## SEC filing metadata
- accession: 0001193125-26-065184
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000119312526065184/0001193125-26-065184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000119312526065184/ofix-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-065184
- JSON: https://secwatch.observer/filing/0001193125-26-065184.json
- Plain text: https://secwatch.observer/filing/0001193125-26-065184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.